Infections due to Escherichia coli producing extended-spectrum β-lactamase among hospitalised patients: factors influencing mortality

Hyle, 2005, Risk factors for increasing multidrug resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species, Clin Infect Dis, 40, 1317, 10.1086/429239 Wiener, 1999, Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes, J Am Med Assoc, 281, 517, 10.1001/jama.281.6.517 Lautenbach, 2001, Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae, Clin Infect Dis, 33, 1288, 10.1086/322667 Schwaber, 2005, High levels of antimicrobial coresistance among extended-spectrum beta-lactamase-producing Enterobacteriaceae, Antimicrob Agents Chemother, 49, 2137, 10.1128/AAC.49.5.2137-2139.2005 Brun-Buisson, 1987, Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae, Lancet, ii, 302, 10.1016/S0140-6736(87)90891-9 Sirot, 1988, Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies, Rev Infect Dis, 10, 850, 10.1093/clinids/10.4.850 Rodriguez-Baño, 2006, Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implication for control, Clin Infect Dis, 42, 37, 10.1086/498519 Naas, 1999, An SHV-derived extended-spectrum β-lactamase in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 43, 1281, 10.1128/AAC.43.5.1281 Cosgrove, 2003, The impact of antimicrobial resistance in health and economic outcomes, Clin Infect Dis, 36, 1433, 10.1086/375081 Schwaber, 2006, Clinical and economic impact of bacteremia with extended-spectrum β-lactamase-producing Enterobacteriaceae, Antimicrob Agents Chemother, 50, 1257, 10.1128/AAC.50.4.1257-1262.2006 Ramphal, 2006, Extended-spectrum β-lactamases and clinical outcomes: current data, Clin Infect Dis, 42, S164, 10.1086/500663 Woodford, 2004, Community and hospital spread Escherichia coli producing CTX-M extended-spectrum beta-lactamase in the U.K, J Antimicrob Chemother, 54, 735, 10.1093/jac/dkh424 Rodriguez-Baño, 2004, Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in non-hospitalized patients, J Clin Microbiol, 42, 1089, 10.1128/JCM.42.3.1089-1094.2004 Peña, 2006, Risk factors for acquisition of extended-spectrum β-lactamase-producing Escherichia coli among hospitalized patients, Clin Microbiol Infect, 12, 279, 10.1111/j.1469-0691.2005.01358.x Ben-Ami, 2006, Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital, Clin Infect Dis, 42, 925, 10.1086/500936 Calbo, 2006, Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamases, J Antimicrob Chemother, 57, 780, 10.1093/jac/dkl035 Schiappa, 1996, Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case–control and molecular epidemiologic investigation, J Infect Dis, 174, 529, 10.1093/infdis/174.3.529 Emery, 1997, Detection and clinical significance of extended-spectrum β-lactamase in tertiary-care medical center, J Clin Microbiol, 35, 2061, 10.1128/JCM.35.8.2061-2067.1997 Paterson, 2001, Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, J Clin Microbiol, 39, 2206, 10.1128/JCM.39.6.2206-2212.2001 Wong-Beringer, 2002, Molecular correlations for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime, Clin Infect Dis, 34, 135, 10.1086/324742 Du, 2002, Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome, Intensive Care Med, 28, 1718, 10.1007/s00134-002-1521-1 Kim, 2002, Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia, J Hosp Infect, 52, 99, 10.1053/jhin.2002.1288 Kim, 2002, Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical results, Antimicrob Agents Chemother, 46, 1481, 10.1128/AAC.46.5.1481-1491.2002 Ho, 2002, Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: a case–control study of risk factors and outcomes, Scand J Infect Dis, 34, 567, 10.1080/00365540210147516 Metan, 2005, Clinical outcomes and therapeutics options of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli, Int J Antimicrob Agents, 26, 254, 10.1016/j.ijantimicag.2005.06.012 Garner, 1988, CDC definitions for nosocomial infections, 1988, Am J Infect Control, 16, 128, 10.1016/0196-6553(88)90053-3 Clinical and Laboratory Standards Institute, 2005 Legrand, 1989, Detection of extended broad-spectrum beta-lactamases in Enterobacteriaceae in four French hospitals, Eur J Clin Microbiol Infect Dis, 8, 527, 10.1007/BF01967473 Peña, 2001, An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum β-lactamase, J Hosp Infect, 47, 53, 10.1053/jhin.2000.0862 Kang, 2004, Bloodstream infections due to extended-spectrum Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy, Antimicrob Agents Chemother, 48, 4574, 10.1128/AAC.48.12.4574-4581.2004 Paterson, 2004, International prospective study of Klebsiella pneumoniae bacteremia: implication of extended-spectrum beta-lactamase production in nosocomial infections, Ann Intern Med, 140, 26, 10.7326/0003-4819-140-1-200401060-00008 Kang, 2005, Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcomes, Antimicrob Agents Chemother, 49, 760, 10.1128/AAC.49.2.760-766.2005 Hyle, 2005, Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Variability by site of infection, Arch Intern Med, 165, 1375, 10.1001/archinte.165.12.1375 Lautenbach, 2001, Extended-spectrum β-lactamase-production Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes, Clin Infect Dis, 32, 1162, 10.1086/319757 Paterson, 2000, Recommendations for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs), Clin Microbiol Infect, 6, 460, 10.1046/j.1469-0691.2000.00107.x Wong-Beringer, 2001, Therapeutic challenges associated with extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae, Pharmacotherapy, 21, 583, 10.1592/phco.21.6.583.34537 Meyer, 1993, Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins, Ann Intern Med, 119, 353, 10.7326/0003-4819-119-5-199309010-00001 Falagas, 2006, Risk factors for the isolation of multi-drug-resistant Acinetobacter baumanii and Pseudomonas aeruginosa: a systematic review of the literature, J Hosp Infect, 64, 7, 10.1016/j.jhin.2006.04.015 Paterson, 2006, The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species, Clin Infect Dis, 43, S43, 10.1086/504476